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Introduction: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe
dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as
assessed by SIB factor scores, in patients with moderately severe-to-severe Alzheimer’s disease (AD).
Methods: This was a retrospective analysis of a 26-week, multicenter, randomized, double-blind, placebo-controlled
study of oral rivastigmine conducted in Spain. Previously reported outcome measures included the full SIB. Current
analyses examined calculated scores and effect sizes for the change from baseline at Week 26 on: newly defined
SIB subscales (derived by a factor analysis of the 40 SIB items, using the PROC FACTOR function (SAS)); previously
defined memory, language and praxis subscales (derived by previous analysis of the nine SIB domains); and the
individual SIB items. Treatment differences were assessed.
Results: SIB data were provided by 104 rivastigmine-treated patients and 106 patients receiving placebo
(Intent-To-Treat Last Observation Carried Forward population). Significantly less decline was observed on the
previously defined memory and language subscales, and the newly defined working memory/memory subscale in
rivastigmine-treated patients (all P < 0.05 versus placebo). Calculation of effect sizes demonstrated numerically
greater efficacy of rivastigmine versus placebo on each of the subscales, and a broad range of SIB items; greatest
effect sizes were observed on SIB items assessing the current month (effect size = 0.30) and digit span series
(effect size = 0.33).
Conclusions: These data suggest the observed efficacy of rivastigmine in moderately severe-to-severe AD is likely
a cumulative effect across a range of tasks. Rivastigmine demonstrates broad cognitive efficacy in this patient population.Introduction
The cholinesterase inhibitor rivastigmine has demonstrated
efficacy on activities of daily living (ADL), cognition and be-
havior in clinical trials of patients with mild-to-moderately
severe Alzheimer’s disease (AD) [1-4]. Currently, oral
(6 to 12 mg/day) and transdermal rivastigmine
(4.6 mg/24 h, 9.5 mg/24 h and 13.3 mg/24 h) are
approved in the USA for the symptomatic treatment of
mild-to-moderate AD [5,6]. A previously reported
pooled analysis of data from clinical trials investigating* Correspondence: steven.ferris@nyumc.org
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stated.the efficacy of rivastigmine in patients with mild-
to-moderately severe AD suggested that rivastigmine
may also benefit patients at more advanced stages of
the disease [7]. Indeed, the rivastigmine transdermal
patch has recently been approved in the USA for the
symptomatic treatment of severe AD [5]. This approval
was based on the findings of the ACTivities of daily
living and cognitION (ACTION) study, a large, 24-week,
multicenter, randomized, active-controlled trial assessing
the comparative efficacy and safety of 13.3 mg/24 h versus
4.6 mg/24 h rivastigmine transdermal patch in patients
with severe AD [8].
The efficacy and safety of oral rivastigmine in Spanish
patients with moderately severe-to-severe AD (Mini-
Mental State Examination (MMSE) score of 5 to 12) weretd. This is an Open Access article distributed under the terms of the Creative
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randomized, double-blind, placebo-controlled trial
[9]. In this study, rivastigmine treatment was associated
with significantly less decline on the Severe Impairment
Battery (SIB) and significant improvements on the
MMSE and Alzheimer’s Disease Cooperative Study-
Clinical Global Impression of Change (ADCS-CGIC)
scale, compared with placebo [9]. A trend towards
improvement, or reduced decline, was also seen in
rivastigmine-treated patients compared with placebo on
the 10-item Neuropsychiatric Inventory (NPI-10), the
4-item NPI (NPI-4), the Global Deterioration Scale
(GDS) and the Alzheimer’s Disease Cooperative Study-
Activities of Daily Living (ADCS-ADL) scale [9]. Of the
assessment scales used in this study, the SIB was
specifically designed and validated for use in patients
with severe dementia, since they may have difficulty
completing more challenging standard neuropsychological
assessments, [10-12] such as the Alzheimer’s Disease
Assessment Scale-cognitive subscale (ADAS-cog).
The SIB is a performance-based measure that assesses
nine symptom domains: attention, language, orientation,
memory, praxis, visuospatial perception, construction,
social skills and orientating head to name [10-12].
Several variations of this test have been developed, with
a range of possible total scores [10-12]. One such
version of the SIB assesses patients on 40 items (ques-
tions) to give a total score ranging from 0 to 100, where a
lower score is indicative of more severe impairment [11].
Previous analyses have grouped the nine domains of
the SIB into three higher-order subscales: memory, lan-
guage and praxis (Table 1) [13]. However, the specific
cognitive functions comprising these higher-order
subscales are broad; for example, the language domain
contains items that assess more than just language
(for example, naming the months of the year, which
could also be considered a memory assessment). Wider
domain coverage is also true for the memory and praxisTable 1 Previous organization of the SIB domains into
higher-order subscales [13]










SIB, Severe Impairment Battery.subscales. Redefining the subscales of the SIB using a
new factor analysis of the 40 individual SIB items, as
opposed to the broad SIB domains, as well as examining
treatment effects on individual items, may facilitate
further investigation of the efficacy of rivastigmine
on more specific aspects of cognition in patients with
severe AD.
The aim of the current post-hoc analysis was to further
investigate the efficacy of oral rivastigmine on cognition
in severe AD, using SIB item data from the previously
reported clinical trial of oral rivastigmine in moderately
severe-to-severe AD [9]. More specifically, the subscales
of the SIB were redefined by performing a factor analysis
of the individual items, as opposed to starting with the
previously defined symptom domains. We investigated
the pattern of efficacy of rivastigmine 1) on these newly
defined subscales; 2) on the memory, language and
praxis higher-order subscales of the SIB derived by a
previous analysis [13]; and 3) for each of the individual
SIB items.Methods
This was a post-hoc analysis of a 26-week, multicenter,
randomized, double-blind, placebo-controlled, parallel-
group study conducted in Spain that evaluated oral
rivastigmine treatment in patients with moderately
severe-to-severe AD [9]. The full details of the design and
conduct of this study have been published previously
[9]. Briefly, patients were male or female, aged 55 years
or older, with probable AD (Diagnostic and Statistical
Manual of Mental Disorders, 4th edition and the National
Institute of Neurological and Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disorders
Association criteria) of moderately severe-to-severe
intensity (MMSE score 5 to 12, GDS stage 5 to 6) [9].
Patients randomized to rivastigmine were up-titrated to
the target dose of 6 mg rivastigmine capsules twice-daily
(bid) in four-week steps (using 1.5 mg bid, 3 mg bid and
4.5 mg bid as intermediate doses) [9]. This titration
schedule was modified in the event of any tolerability
issues. Outcome measures included the change from
baseline at Week 26 on the SIB [9]. This study received
ethical committee approval and was conducted according
to the ethical principles of the Declaration of Helsinki, as
revised in 2000 [9].
Baseline SIB data from this study were used to
perform a new factor analysis to establish a ‘best fit’ for
each of the 40 individual SIB items into possible new
subscales determined by the factor analysis. For this new
factor analysis, the PROC FACTOR function in SAS was
used. Initial common factor extraction was performed
using the principal component method. Estimates of
loadings were obtained using varimax rotation. Items
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factor scores.
The least-squares (LS) mean change from baseline at
Week 26 on the previously published (memory, language
and praxis) [13] and newly defined subscales of the SIB
were calculated for the Intent-To-Treat Last Observation
Carried Forward (ITT-LOCF) population. Additional
analyses were also performed based on the Observed
Case (OC) population. For the ITT-LOCF approach, the
statistical significance of treatment differences was assessed
using an analysis of covariance (ANCOVA) model, with
treatment and center as factors, and baseline as a
covariate. For the ITT-OC approach, the statistical
significance of treatment differences was assessed using
a repeated measure ANCOVA model, with treatment,
center, time-point and treatment-by-time point as
factors, and baseline as a covariate. P-values were calcu-
lated from LS means.
Effect sizes (Cohen’s d) were calculated, based on mean
values, to compare the change from baseline at Week 26
on the newly defined SIB subscales, the previously defined
SIB subscales and each of the individual items of the SIB
in patients randomized to receive rivastigmine or placebo.
Results
Patients
In the 26-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group trial on which this
analysis is based, 218 patients were randomized (1:1) to
receive rivastigmine or placebo [9]. Five rivastigmine-
treated patients and three patients in the placebo group
did not provide a post-treatment SIB assessment and
were excluded from the analyses. Therefore, the ITT-
LOCF population comprised 210 patients (104 in the
rivastigmine group, and 106 in the placebo group) [9].
The ITT-OC population at Week 26 comprised 194
patients (96 in the rivastigmine group and 98 in the
placebo group). At Week 26, the mean (standard
deviation (SD)) dose of rivastigmine received by the
rivastigmine group was 9.8 (2.8) mg/day [9].
At baseline, both treatment groups were similar in terms
of their baseline demographics and patient characteristics.
The mean age of the rivastigmine-treated group and the
placebo group was 78.0 (range 60 to 89) and 77.2 (range
57 to 92) years, respectively. Seventy-eight percent of the
rivastigmine-treated patients and 76% of the placebo
group were female. The mean (SD) MMSE score at
baseline was 9.0 (2.2) in the rivastigmine group and
8.7 (2.2) in the placebo group, indicating moderately
severe-to-severe impairment [9].
Factor analyses
The new factor analysis performed on the SIB at baseline
allocated each of the 40 individual items to one of fivefactors. Allocation was based on which factor was
associated with the highest factor score for each
individual item (Table 2). The individual items allocated
to each factor, and their corresponding SIB domain, are
summarized in Table 3. Based on the individual items
comprising these factors and their clinical relevance, we
named Factor 1, visual; Factor 2, language; Factor 3,
working memory/memory; Factor 4, praxis and social
skills; and Factor 5, naming.
Efficacy of rivastigmine on the previously defined memory,
language and praxis higher-order subscales of the SIB
Using the three subscales derived from a previous analysis
[13], significantly reduced decline was seen on the
memory (least-squares mean (standard error) change
from baseline at Week 26: rivastigmine, -0.40 (0.46);
placebo, -1.92 (0.47); P = 0.010) and language (rivastigmine,
-0.48 (0.76); placebo, -2.40 (0.77); P = 0.045) higher-
order subscales of the SIB. A trend towards reduced
decline, narrowly missing significance, was also
observed on the praxis higher-order subscale of the SIB
in rivastigmine-treated patients compared with placebo
(rivastigmine, -0.33 (0.45); placebo, -1.43 (0.46); P = 0.051).
Calculated effect sizes showed numerically less decline
from baseline at Week 26 with rivastigmine versus
placebo on the memory (effect size: 0.26) language (0.27)
and praxis (0.24) subscales of the SIB.
Efficacy of rivastigmine on the newly defined SIB
subscales: visual; language; working memory/memory;
praxis and social skills; and naming
A significant reduction in decline was seen from baseline
at Week 26 in rivastigmine-treated patients compared
with placebo on the working memory/memory subscale
(Factor 3; P = 0.018; Figure 1). Despite an apparent trend
towards reduced decline in rivastigmine-treated patients
compared with placebo on the visual (Factor 1), language
(Factor 2), praxis and social skills (Factor 4), and naming
(Factor 5) subscales, these differences did not reach
significance (P = 0.056, P = 0.056, P = 0.117 and P = 0.072,
respectively; Figure 1). Based on effect sizes, numerically
less decline was observed in patients randomized to
rivastigmine compared with placebo on all five newly
defined SIB subscales (visual, 0.21; language, 0.22;
working memory/memory, 0.28; praxis and social
skills 0.12; naming, 0.19). Supporting the ITT-LOCF
analysis, the ITT-OC analysis also demonstrated
significantly less decline with oral rivastigmine versus
placebo on the working memory/memory subscale
(P = 0.038).
Efficacy of rivastigmine on the individual items of the SIB
Calculation of treatment effect sizes for each of the
individual items demonstrated efficacy of rivastigmine
Table 2 Factor scores derived by factor analysis to allocate the SIB items into new subscales














1a: Shake hands 0.18637 0.10742 0.14187 0.46777 0.06278
1b: Follow directions 0.03926 0.16075 0.09979 0.72810 −0.02260
1c: Sit/move to table/pull tray 0.14512 0.07164 0.03912 0.81773 0.09756
2: Examiner’s name (immediate recall) 0.19391 0.01890 0.35278 0.20451 0.00918
3: Subject’s name 0.13280 0.09591 0.11500 0.27894 0.13269
4a: Write name 0.14911 0.83191 0.21540 −0.01825 −0.13753
4b: Copy name 0.18811 0.79331 0.22121 0.02954 −0.17792
5: Current month 0.09048 0.10255 0.16135 −0.00452 0.08214
6: Months of the year −0.08840 0.44571 0.16330 0.06817 0.13195
7: City 0.03403 0.23398 0.47705 0.03550 0.13178
8a + 8b: Descriptive naming (cup + spoon) 0.19170 0.11481 0.45178 0.17732 0.53765
9a: Reading comprehension 0.04419 0.56384 0.01299 0.09907 0.24333
9b: Verbal comprehension 0.10071 0.58147 0.04924 0.17725 0.22978
9c: Reading 0.06602 0.75731 −0.03219 0.10638 0.12338
10: Sentence recall 0.12520 0.43543 0.27214 0.11551 0.15668
11a + 11b: Repetition (people spend money + baby) 0.17676 0.15277 0.29899 0.46208 0.21274
12: Digit span (series) −0.01152 0.12864 0.39120 0.09214 0.02801
13: Verbal fluency 0.22551 0.00574 0.60501 0.16787 0.25116
14: Examiner’s name (delayed recall) 0.02598 0.04244 0.22845 0.06847 −0.00027
15 + 20: Naming object in photograph (cup + spoon) 0.20978 0.21774 0.18377 0.15042 0.67844
16 + 18: Using cup (photograph + object) 0.24127 0.04208 0.48144 0.06123 0.41299
17 + 22: Naming object (cup + spoon) 0.19141 0.15694 0.16444 0.19876 0.70735
19 + 24: Forced choice naming (cup + spoon) 0.34707 0.04743 0.04278 0.33749 0.37978
21 + 23: Using spoon (photograph + object) 0.24747 0.06307 0.40561 0.15432 0.39211
25: Immediate recall of objects (cup + spoon) 0.30110 0.10494 0.46109 0.22645 0.17432
26 + 30a + 30b: Color naming (blue + red + green) 0.52207 0.21932 0.07852 0.03810 0.36658
27: Color matching 0.59979 0.05950 0.12284 0.12189 0.17387
28: Colored block 0.56639 0.10328 0.02037 0.12734 0.05381
29: Color discrimination 0.68207 0.13255 0.28264 0.15338 0.11077
31: Shape matching 0.54832 0.13483 0.23207 0.22148 0.32796
32: Shape 0.55816 −0.04496 0.22437 0.19948 0.09445
33: Shape discrimination 0.58847 0.06018 0.38125 0.26172 0.10459
30c + 34a + 34b: Shape identification (square + circle + triangle) 0.36032 0.26761 0.33625 0.21808 0.20124
35a: Drawing (circle) 0.23055 0.20295 0.28592 0.04922 0.25047
35b: Drawing (square) 0.23820 0.30433 0.47077 0.06087 0.13839
36: Auditory span 0.21216 0.12792 0.28611 0.27011 0.10342
37: Visual span 0.26459 0.28920 0.30645 0.17403 0.30167
38: Delayed recall of objects (cup + spoon) 0.37135 −0.04291 0.47166 0.16280 0.07484
39: Orientation to name 0.15592 0.01837 0.16938 0.58642 0.14839
40: Language ability (free conversation) 0.16147 −0.07097 0.40767 0.47483 0.16766
SIB, Severe Impairment Battery. Scores were derived using initial common factor extraction and the principal component method, and were based on data from
217 patients. Estimates of loadings were obtained using varimax rotation. SIB items were allocated to factors on the basis of highest score. Items allocated to each
factor are shown in bold.
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Table 3 Allocation of the individual items of the SIB into five new subscales
New subscale SIB item SIB domain [10]
Factor 1: visual 26 + 30a + 30b: Color naming (blue + red + green) Language
27: Color matching Visuospatial perception
28: Colored block Memory
29: Color discrimination Visuospatial perception
30c + 34a + 34b: Shape identification (square + circle + triangle) Language
31: Shape matching Visuospatial perception
32: Shape Memory
33: Shape discrimination Visuospatial perception
Factor 2: language 4a: Write name Language
4b: Copy name Language
6: Months of the year Language
9a: Reading comprehension Language
9b: Verbal comprehension Language
9c: Reading Language
10: Sentence recall Memory
Factor 3: working memory/memory 2: Examiner’s name (immediate recall) Memory
5: Current month Orientation
7: City Orientation
12: Digit span (series) Attention
13: Verbal fluency Language
14: Examiner’s name (delayed recall) Memory
16 + 18: Using cup (photograph + object) Praxis
21 + 23: Using spoon (photograph + object) Praxis
25: Immediate recall of objects (cup + spoon) Memory
35a: Drawing (circle) Construction
35b: Drawing (square) Construction
36: Auditory span Attention
37: Visual span Attention
38: Delayed recall of objects (cup + spoon) Memory
Factor 4: praxis and social skills 1a: Shake hands Social skills
1b: Follow directions Social skills
1c: Sit/move to table/pull tray Social skills
3: Subject’s name Orientation
11a + 11b: Repetition (people spend money + baby) Language
39: Orientation to name Orientating head to name
40: Language ability (free conversation) Language
Factor 5: naming 8a + 8b: Descriptive naming (cup + spoon) Language
15 + 20: Naming object in photograph (cup + spoon) Language
17 + 22: Naming object (cup + spoon) Language
19 + 24: Forced-choice naming (cup + spoon) Language
SIB, Severe Impairment Battery. SIB domain allocation refers to the nine domains of the SIB, to which each of the items have been previously assigned. New
subscales relate to the new factors generated from factor analysis of the 40 individual SIB items.
















































Figure 1 LS mean change from baseline at Week 26 on the
newly defined SIB subscales. LS, least-squares; Stderr, standard
error of the LS mean; SIB, Severe Impairment Battery. Analysis based
on the Intent-To-Treat Last Observation Carried Forward (ITT-LOCF)
population. P-values (derived from LS mean) calculated using an
analysis of covariance (ANCOVA) model with treatment and center
as factors, and baseline as a covariate. Negative change scores
indicate deterioration. Newly defined SIB subscales named Factor
1 = visual, Factor 2 = language, Factor 3 = working memory/memory,
Factor 4 = praxis and social skills, Factor 5 = naming. *P < 0.05 versus
placebo.
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defined SIB subscales (Figure 2). Greatest effect sizes
(0.30 and above) were observed on items assessing the
current month (item 5; effect size 0.30) and digit span
series (item 12; 0.33).
Effect sizes above 0.2 (range 0.21 to 0.28) were
observed on these items: shake hands (1a), write name
(4a), copy name (4b), city (7), verbal comprehension
(9b), naming object (cup + spoon; 17 + 22), using
spoon (21 + 23) and shape discrimination (33). Effect
sizes of 0.1 and above (range 0.10 to 0.19) were observed
on the following items: directions (1b), subject’s name
(3), reading comprehension (9a), naming object in
photograph (15 + 20), using cup (16 + 18), color naming
(26 + 30a + 30b), color block (28), shape identification
(30c + 34a + 34b), drawing circle (35a), auditory span
(36), and orientation to name (39). For all other items
(1c, 2, 6, 8a + 8b, 9c, 10, 11a + 11b, 13, 14, 19 + 24, 25,
27, 29, 31, 32, 35b, 37, 38 and 40) effect sizes were <0.1,and considered similar between rivastigmine and placebo
groups, with the exception of item 25 (immediate recall)
for which the calculated effect size of −0.18 suggested
better performance in the placebo group.Discussion
AD is associated with gradual loss of cholinergic transmission
in the brain, which manifests as progressive deterioration of
cognitive function [14]. As cholinergic deficits correlate with
disease stage, treatment strategies that increase levels of
acetylcholine available in cholinergic synapses may become
more relevant as the disease progresses.
Several clinical studies and retrospective analyses of
trial databases have investigated the efficacy of rivastigmine
in patients with moderately severe AD. Analysis of a
52-week study of oral rivastigmine investigated the
long-term efficacy of rivastigmine in patients with AD
stratified by baseline dementia severity, determined
using the GDS [15]. Patients with a GDS score ≥5
(moderately severe disease) receiving 1 to 4 mg/day or
6 to 12 mg/day rivastigmine capsules showed signifi-
cant improvements compared with placebo on the
ADAS-cog during an initial 26-week, double-blind
treatment phase [15]. At Week 52, following a further
26 weeks of open-label treatment with 6 to 12 mg/day
rivastigmine, ADAS-cog performance was significantly
superior in treated patients compared with projected
placebo [15]. These findings suggest that rivastigmine
may have sustained cognitive benefits in patients with
moderately severe AD. Furthermore, retrospective,
pooled analysis of data from three randomized, placebo-
controlled, double-blind, six-month clinical trials of patients
with probable AD (MMSE score of 10 to 26) provided
evidence for a cognitive benefit of rivastigmine treatment
in the subset of patients with more severe AD (MMSE
score of 10 to 12) [7]. In support of these findings, further
pooled analysis of these studies, in which patients
randomized to receive 6 to 12 mg/day rivastigmine
capsules were stratified according to dementia severity,
reported significant efficacy of rivastigmine versus placebo
on the ADAS-cog across all disease stages, including
moderately severe AD (MMSE score of ≤ 15) [16].
Although these analyses suggest cognitive benefits
of rivastigmine in moderately severe AD, the scales
commonly used to assess cognitive efficacy in clinical
trials of patients with mild-to-moderately severe AD, for
example, the ADAS-cog, may not be sensitive to the full
range of cognitive changes in patients with severe AD,
owing to floor effects and limited ability of these patients
to complete assessments. Tests designed to be sensitive
within the capabilities of patients with more advanced













b 4a 4b 6 9a 9b 9
c


















































Figure 2 Effect sizes based on mean change from baseline at Week 26 on individual SIB items. SIB, Severe Impairment Battery.
Analysis based on the Intent-To-Treat Last Observation Carried Forward (ITT-LOCF) population. Negative change scores indicate
deterioration.
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cognitive function.
A previous randomized, placebo-controlled clinical
trial reported significant efficacy of rivastigmine on the
total SIB in patients with moderately severe-to-severe
AD [9]; SIB data from this trial formed the basis of
the current analysis, in which we sought to further
investigate the pattern of cognitive efficacy of rivastigmine
in patients with severe AD. Rivastigmine treatment was
associated with significant efficacy on the higher-order
memory and language subscales of the SIB, as defined by
a previous analysis of the nine SIB domains [13]. A trend
toward numerically greater efficacy was also observed on
the praxis subscale.
In the version of the SIB used in this analysis, the nine
domains of the SIB comprised 40 items, which assess a
diverse range of cognitive impairments, from awareness
of the current month, to ability to identify everyday
objects, for example, a cup and spoon. Given the broad
range of cognitive functions assessed by the items
encompassed in the nine SIB domains, we performed a
new factor analysis of the SIB using the individual items,
as opposed to domains, which allocated the 40 items
to one of five factors (two more than the previously
published analysis). Rivastigmine demonstrated significant
efficacy compared with placebo on the new subscale we
termed working memory/memory, based on the range of
SIB items encompassed in this subscale. Based on effect
sizes, a numerical trend toward greater efficacy was also
observed on each of the newly defined subscales inrivastigmine-treated patients compared with placebo. The
lack of a significant treatment effect on the visual,
language, praxis and social skills, and naming factors may
have resulted from floor and ceiling effects on some
individual SIB items. Since the majority of studies in AD
have been performed in patients of mild-to-moderate
disease stage, issues related to these effects in patients
with severe AD have not been routinely addressed in
clinical studies. In the current analysis, it is possible that
floor or ceiling effects at baseline may have influenced
loading on to factors, and the ability to observe treatment
effects versus placebo.
In addition to investigating efficacy on previously
defined and newly defined subscales, we also calculated
the magnitude of treatment effects on individual SIB
items. Efficacy on these individual items may translate
into clinically meaningful benefits for patients and their
caregivers. Greatest effect sizes were observed on items
assessing current month and memory span (digit series).
Both of these items form part of the newly defined
working memory/memory subscale and the previously
defined memory subscale, and may account in part for
the significant efficacy of treatment observed on these
subscales. However, overall, rivastigmine was shown to
demonstrate efficacy on a wide range of items (based on
effect sizes), spanning across both the newly defined and
previously defined SIB subscales. These findings suggest
that the observed efficacy of rivastigmine on the SIB is
not a result of efficacy on a few individual items or a few
cognitive domains, but rather is a fairly consistent,
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tasks. These findings are encouraging, as they suggest
rivastigmine may have broad cognitive efficacy in severe
AD.
Limitations of this study include its retrospective
nature; this was an exploratory analysis and was only
intended to be hypothesis forming. This study was not
powered to detect differences on the individual SIB
items, previously defined subscales, or on the new
subscales derived by factor analysis of the SIB items.
These considerations may reduce the robustness of
these results. Larger studies are needed to confirm these
findings, and to further investigate the cognitive efficacy
of oral rivastigmine in patients with severe AD.
Additional information on the pattern of cognitive benefit
of rivastigmine in patients with severe AD is provided
by the ACTION study (ClinicalTrials.gov identifier
NCT00948766) [8]. The SIB was a co-primary outcome
measure to assess cognition in this study. The ACTION
study demonstrated significantly greater efficacy of
13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on
cognition, as measured by the change from baseline at
Week 24 on the total SIB score, without a marked
impact on safety and tolerability [8]. To our knowledge,
this was the first clinical trial of the rivastigmine patch
in patients with severe AD; primary and post-hoc analyses
of data obtained in this study will allow investigation
into the use and specific cognitive effects of the high
dose 13.3 mg/24 h rivastigmine patch in this indication.
Furthermore, given that 13.3 mg/24 h patch is now
approved for the symptomatic treatment of severe AD in
the USA [5], investigating physician experiences with
high-dose patch in this indication will provide further
information on how trial findings may translate into
clinical practice.
Conclusions
In this post-hoc analysis, oral rivastigmine demonstrated
efficacy on the previously defined memory and language
subscales, newly defined working memory/memory
subscales, and several individual items of the SIB in
patients with moderately severe-to-severe AD. The
cumulative effect observed across a broad range of
tasks corroborates previous evidence, and reinforces
that rivastigmine may be an effective therapy in the
treatment of severe AD.
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